1. Articles in category: Immune Therapy

    1-24 of 349 1 2 3 4 ... 13 14 15 »
    1. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      BMC Immunol. 2017 Jul 07;18(1):36

      Authors: Mou W, Han W, Ma X, Wang X, Qin H, Zhao W, Ren X, Chen X, Yang W, Cheng H, Wang X, Zhang H, Ni X, Wang H, Gui J

      Abstract BACKGROUND: Previous studies have shown that γδ TFH cells are capable of modulating antibody production in immunized and infected mouse model.

      Read Full Article
      Mentions: Antibody
    2. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.

      Oncoimmunology. 2017;6(6):e1320625

      Authors: Hoseini SS, Dobrenkov K, Pankov D, Xu XL, Cheung NV

      Abstract Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells. Despite their success in lymphoblastic leukemia, solid tumors have been more recalcitrant.

      Read Full Article
    3. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

      MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

      Oncoimmunology. 2017;6(6):e1316439

      Authors: Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L

      Read Full Article
      Mentions: MYCN
    4. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

      Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

      Oncoimmunology. 2017;6(6):e1320626

      Authors: Layer JP, Kronmüller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, Althoff K, Schramm A, Westermann F, Peifer M, Hartmann G, Tüting T, Kolanus W, Fischer M, Schulte J, Hölzel M

      Read Full Article
      Mentions: MYCN
    5. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Mol Ther. 2017 Jul 01;:

      Authors: Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL

      Read Full Article
      Mentions: ALK
    6. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.

      Tumour Biol. 2017 Jul;39(7):1010428317701309

      Authors: Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG

      Abstract The cancer germline antigens MAGE-A1, MAGE-A3, and NY-ESO-1 can be used to target relapsed or therapy-resistant malignant solid tumors, and previous studies have demonstrated that these antigens can be epigenetically upregulated on the surface of tumor cells following exposure to low-dose demethylating chemotherapy agents, such as decitabine. The extent to which cancer germline antigen cytotoxic T lymphocytes can be reliably expanded from healthy donors has not been well characterized, specifically in ...

      Read Full Article
    7. Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      Treatment of Transient Peripheral Neuropathy During Chimeric 14.18 Antibody Therapy in Children With Neuroblastoma: A Case Series.

      J Pediatr Hematol Oncol. 2017 Jul 03;:

      Authors: Ari P, Kars M, Meany H, Pestieau S

      Abstract Children with high-risk neuroblastoma are currently treated with a chimeric monoclonal antibody against GD2 ganglioside (chimeric 14.18). The treatment improves survival but causes transient neuropathic pain-like syndrome.

      Read Full Article
      Mentions: Antibody Treatment
    8. Assessment of Anti-Tumor Cytotoxic Activity of Naturally Occurring Antibodies in Human Serum or Plasma.

      Assessment of Anti-Tumor Cytotoxic Activity of Naturally Occurring Antibodies in Human Serum or Plasma.

      Methods Mol Biol. 2017;1643:105-110

      Authors: Schwartz-Albiez R, Dill O

      Abstract A small percentage of the Western population carries antibodies in the peripheral blood, which are able to kill human tumors such as neuroblastoma or melanoma. Several observations indicate that these antibodies, preferentially of IgM isotype, belong to the class of naturally occurring antibodies.

      Read Full Article
    9. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

      HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

      Front Immunol. 2017;8:675

      Authors: Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM

      Read Full Article
      Mentions: COG Immunotherapy
    10. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.

      Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.

      Pediatr Neurol. 2017 May 19;:

      Authors: Pranzatelli MR, Tate ED

      Abstract BACKGROUND: Although pulse-dose dexamethasone is increasingly favored for treating pediatric opsoclonus-myoclonus syndrome (OMS), and multimodal immunotherapy is associated with improved clinical response, there have been no neuroimmunologic studies of dexamethasone-based multimodal disease-modifying therapy. METHODS: In this observational retrospective study, 19 children with OMS (with or without associated neuroblastoma) underwent multibiomarker evaluation for neuroinflammation. Nine children of varying OMS severity, duration, and treatment status were treated empirically with pulse dexamethasone, intravenous immunoglobulin (IVIg), and rituximab combination immunotherapy (DEXIR-CI). Another ...

      Read Full Article
    11. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.

      J Immunother. 2017 Jun 15;:

      Authors: Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA, Asgharzadeh S

      Read Full Article
      Mentions: NK Cells
    12. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.

      "Thirty-nine of 451 evaluable tumors (9%) expressed PD-L1 in at least 1% of tumor cells. The highest frequency histotypes comprised Burkitt lymphoma (80%; 8 of 10 tumors), glioblastoma multiforme (36%; 5 of 14 tumors), and neuroblastoma (14%; 17 of 118 tumors). PD-L1 staining was associated with inferior survival among patients with neuroblastoma (P = .004). Seventy-four percent of tumors contained lymphocytes and/or macrophages. Macrophages were significantly more likely to be identified in PD-L1-positive versus PD-L1-negative tumors (P < .001).  A subset of diagnostic pediatric cancers exhibit PD-L1 expression, whereas a much larger fraction demonstrates infiltration with tumor-associated lymphocytes. PD-L1 expression may ...

      Read Full Article
      Mentions: PD-1
    13. Car T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

      "Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the cells had poor expansion and long-term persistence. We developed a third-generation GD2-CAR (GD2-CAR3) and hypothesized that GD2-CAR3 T cells (CARTs) would be safe and effective. This phase 1 study enrolled relapsed or refractory NB patients in three cohorts. Cohort 1 received CART alone, cohort 2 received CARTs plus cyclophosphamide and fludarabine (Cy/Flu), and cohort 3 was treated with CARTs, Cy/Flu, and a programmed death-1 (PD-1) inhibitor. Eleven patients were treated with CARTs. The infusions were safe, and no ...

      Read Full Article
      Mentions: PD-1
    14. YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

      "Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced positive top line results from a pivotal study of 131I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 months average survival for the patients treated with 131I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have ...

      Read Full Article
    15. Orphan designation: Chimeric monoclonal antibody against GD2, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 8 November 2012, orphan designation (EU/3/12/1062) was granted by the European Commission to Apeiron Biologics AG, Austria, for chimeric monoclonal antibody against GD2 for the treatment of neuroblastoma. This medicine is now known as dinutuximab beta. Chimeric monoclonal antibody against GD2 has been authorised in the EU as Dinutuximab beta Apeiron since 8 May 2017. What is neuroblastoma?

      Read Full Article
      Mentions: Antibody Treatment
    16. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors

      Significant antitumor effects have been observed in a variety of malignancies via blockade of immune checkpoints. Interaction of programmed death 1 (PD-1) with its ligands PD-L1 and PD-L2 suppresses T-cell function and restricts immune-mediated tumor killing. We examined expression of these proteins in children with solid tumors, as expression may serve as biomarkers of response to this class of drugs.

      Read Full Article
      Mentions: PD-1 Biomarkers
    17. Testing a new immunotherapy treatment for neuroblastoma

      Testing a new immunotherapy treatment for neuroblastoma

      Immunotherapies are changing the outlook for many cancer patients.

      Drugs that block cancer cells from deflecting an immune attack are now routinely used to treat advanced skin and kidney cancers, and are showing promise in other types of cancer too.

      But cancers are complex and diverse – what works well against one type of cancer might have little effect against another. The immunotherapies available for some patients aren’t a magic bullet that will work for everyone.

      Read Full Article
    18. Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      Chemoimmunotherapeutic effect of combined treatment with ex vivo generated antigen-presenting immune cells and conventional antitumor agents in a mouse neuroblastoma model.

      J Pediatr Surg. 2017 Apr 21;:

      Authors: Inoue S, Setoyama Y, Odaka A, Kitagawa D, Beck Y

      Read Full Article
      Mentions: Treatment
    19. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    20. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

      Chimeric antigen receptor–modified T cells (CAR T cells) produce proinflammatory cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit their functionality against solid tumors. In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing.

      Read Full Article
      Mentions: Antibody PD-1
    1-24 of 349 1 2 3 4 ... 13 14 15 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (4 articles) Immunotherapy
    2. (3 articles) Antibody
    3. (2 articles) MYCN
    4. (1 articles) ALK
  5. General Informations in the News

    1. (2 articles) Treatment
  6. Treatments in the News

    1. (1 articles) Chemotherapy